Department of Pharmacy Practice & Science, College of Pharmacy, University of Iowa, Iowa City, Iowa.
Division of Health Outcomes and Pharmacy Practice, College of Pharmacy, University of Texas, Austin, Texas.
Pharmacotherapy. 2018 Mar;38(3):309-318. doi: 10.1002/phar.2083. Epub 2018 Feb 23.
The objectives of this study were to determine if hypertensive patients with comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) receiving a pharmacist intervention had a greater reduction in mean blood pressure (BP) and improved BP control at 9 months compared with those receiving usual care; and compare Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guideline and 2014 guideline (JNC 8) BP control rates in patients with DM and/or CKD.
This cluster randomized trial included 32 medical offices in 15 states. Clinical pharmacists made treatment recommendations to physicians at intervention sites. This post hoc analysis evaluated mean BP and BP control rates in the intervention and control groups.
The study included 335 patients (227 intervention, 108 control) when mean BP and control rates were evaluated by JNC 7 inclusion and control criteria. When JNC 8 inclusion and control criteria were applied, 241 patients (165 intervention, 76 control) remained and were included in the analysis. The pharmacist-intervention group had significantly greater mean systolic blood pressure reduction compared with usual care at 9 months (8.64 mm Hg; 95% confidence interval [CI] -12.8 to -4.49, p<0.001). The pharmacist-intervention group had significantly higher BP control at 9 months than usual care by either the JNC 7 or JNC 8 inclusion and control groups (adjusted odds ratio [OR] 1.97, 95% CI 1.01-3.86, p=0.0470 and OR 2.16, 95% CI 1.21-3.85, p=0.0102, respectively).
This study demonstrated that a physician-pharmacist collaborative intervention was effective in reducing mean systolic BP and improving BP control in patients with uncontrolled hypertension with DM and/or CKD, regardless of which BP guidelines were used.
本研究旨在确定接受药师干预的合并糖尿病(DM)和/或慢性肾脏病(CKD)的高血压患者与接受常规护理的患者相比,在 9 个月时的平均血压(BP)是否有更大程度的降低以及血压控制是否得到改善;并比较 DM 和/或 CKD 患者的第七次联合国家委员会预防、检测、评估和治疗高血压报告(JNC 7)指南和 2014 年指南(JNC 8)的 BP 控制率。
这项聚类随机试验纳入了来自 15 个州的 32 家医疗办公室。临床药师向干预点的医生提出治疗建议。本事后分析评估了干预组和对照组的平均 BP 和 BP 控制率。
当根据 JNC 7 纳入和对照组标准评估平均 BP 和控制率时,研究共纳入 335 名患者(227 名干预组,108 名对照组)。当应用 JNC 8 纳入和对照组标准时,有 241 名患者(165 名干预组,76 名对照组)仍保留并纳入分析。与常规护理相比,药师干预组在 9 个月时的平均收缩压降低更为显著(8.64mmHg;95%置信区间[CI]-12.8 至-4.49,p<0.001)。通过 JNC 7 或 JNC 8 纳入和对照组标准,药师干预组在 9 个月时的 BP 控制率显著高于常规护理组(调整后的优势比[OR]1.97,95%CI 1.01-3.86,p=0.0470 和 OR 2.16,95%CI 1.21-3.85,p=0.0102)。
本研究表明,医生-药师合作干预可有效降低未经控制的高血压合并 DM 和/或 CKD 患者的平均收缩压,并改善血压控制,无论使用哪种 BP 指南。